Business Description
Ascendis Pharma AS
NAICS : 325412
SIC : 2836
ISIN : DK0060615755
Share Class Description:
MEX:ASNDN: ADRTotal Employee Number:
1,189Compare
Compare
Traded in other countries / regions
ASND.USAA1SN34.BrazilA71.GermanyASNDN.Mexico IPO Date
2017-11-10Description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.64 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 1.84 | |||||
Debt-to-EBITDA | -90.63 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 5.73 | |||||
Beneish M-Score | 3.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 143.2 | |||||
3-Year EBITDA Growth Rate | 39.6 | |||||
3-Year EPS without NRI Growth Rate | 31.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 48.36 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.94 | |||||
9-Day RSI | 69.68 | |||||
14-Day RSI | 59.95 | |||||
3-1 Month Momentum % | -0.77 | |||||
6-1 Month Momentum % | 4.72 | |||||
12-1 Month Momentum % | 23.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1 | |||||
Quick Ratio | 0.72 | |||||
Cash Ratio | 0.51 | |||||
Days Inventory | 1149.13 | |||||
Days Sales Outstanding | 52.85 | |||||
Days Payable | 323.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -0.44 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.05 | |||||
Operating Margin % | -1.19 | |||||
Net Margin % | 56.74 | |||||
EBITDA Margin % | -1.14 | |||||
FCF Margin % | 6.96 | |||||
OCF Margin % | 6.96 | |||||
ROE % | Neg. Equity | |||||
ROA % | 37.63 | |||||
3-Year ROIIC % | 80.27 | |||||
ROC (Joel Greenblatt) % | -24.13 | |||||
ROCE % | -8.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.94 | |||||
Forward PE Ratio | 42.65 | |||||
PE Ratio without NRI | 24.32 | |||||
PEG Ratio | 1.1 | |||||
PS Ratio | 14.74 | |||||
PB Ratio | 26.03 | |||||
Price-to-Tangible-Book | 26.24 | |||||
Price-to-Free-Cash-Flow | 201.97 | |||||
Price-to-Operating-Cash-Flow | 201.97 | |||||
EV-to-EBIT | -504.16 | |||||
EV-to-Forward-EBIT | 66.15 | |||||
EV-to-EBITDA | -1395.11 | |||||
EV-to-Forward-EBITDA | 61.66 | |||||
EV-to-Revenue | 15.83 | |||||
EV-to-Forward-Revenue | 9.57 | |||||
EV-to-FCF | 224.5 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.97 | |||||
Earnings Yield (Greenblatt) % | -0.2 | |||||
FCF Yield % | 0.46 |
GF Valueâ„¢
Ascendis Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascendis Pharma AS Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 141 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 140 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 44 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 43 days | ||
| First quarter earnings conference call for 2026 | 2026-05-01 16:30 | 3,851.44 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-01 | 3,851.44 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 11:10 | 3,851.44 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-11 16:30 | 3,801.22 (+0.00%) | ||
| Annual report for 2025 | 2026-02-11 | 3,801.22 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-11 | 3,801.22 (+0.00%) |
Show
Entries
Press Release
Articles on Ascendis Pharma AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers